Renal Cancer - Results from #2140

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. March 10, 2021

Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? March 10, 2021

Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data. March 9, 2021

Comprehensive Molecular Characterization and Response to Therapy in FH-Deficient Renal Cell Carcinoma. March 9, 2021

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. March 9, 2021

Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. March 8, 2021

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. March 8, 2021

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. March 8, 2021

Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. March 5, 2021

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. March 5, 2021

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. March 4, 2021

Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients. March 4, 2021

Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. March 3, 2021

Enhanced Recovery after Robot-Assisted Partial Nephrectomy for Cancer: Is it Better for Patients to Have a Quick Discharge? March 3, 2021

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). March 3, 2021

Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation. March 2, 2021

Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. March 2, 2021

Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. March 2, 2021

Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71). March 1, 2021

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. March 1, 2021

Page 108 of 456